**Overview**

Hemophilia A (factor VIII [factor 8] deficiency) and hemophilia B (factor IX [factor 9] deficiency) are X-linked inherited coagulation factor deficiencies that result in lifelong bleeding disorders. The availability of factor replacement products has dramatically improved care for individuals with these conditions. Factor XI products are used to control and prevent bleeding episodes in adults and children with Hemophilia B, for perioperative management in adults and children with Hemophilia B, and for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with Hemophilia B.

**Hemophilia B**

- Rebinyn (coagulation factor IX [recombinant], glycoPEGylated)
- Idelvion (coagulation factor IX [recombinant], albumin fusion protein)
- Alprolix (coagulation factor IX [recombinant], Fc fusion protein)
- Benefix (coagulation factor IX [recombinant]) *
- Ixinity (coagulation factor IX [recombinant])
- Rixubis (coagulation factor IX [recombinant])
- Alphanine SD (coagulation factor IX [human])
- Mononine (coagulation factor IX [human])

**Hemophilia B Complex**

- Bebulin (factor IX complex [human])
- Profilnine (factor IX complex [human])

* Preferred Drug
Coverage Guidelines

Hemophilia B
Authorization may be granted when the following criteria are met, and documentation is provided:
1. Member has diagnosis of hemophilia B

Hemophilia B Complex
Authorization may be granted when ONE of the following criteria are met, and documentation is provided:
1. Member has diagnosis of hemophilia B or bleeding due to low levels of liver dependent coagulation factors
2. Member is using medication for treatment of factor X deficiency (Bebulin only)
3. Member is using medication for treatment of factor II deficiency (Profilnine only)

Continuation of Therapy
All members (including new members) requesting authorization for continuation must meet initial authorization criteria.

Limitations
Approvals will be granted for 36 months.

References

Review History
11/18/2020 – Updated and reviewed at Nov P&T Mtg: Moved from SGM to custom template, Separated Comm/Exch vs. MassHealth; reflected Benefix as preferred, changed approval dates from indefinite to 36 months

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.